Gilles P.
- Country
- France
- Department
- Infectious diseases
Research Overview
- Cohort study of human mpox virus disease
- Evaluation of Safety in HBV Virological Control Using Darunavir, Ritonavir, Dolutegravir Sodium, and Lamivudine in HIV-1/HBV Co-infected Patients
- Evaluation of Budigalimab and ABBV-382 Efficacy, Safety, and Pharmacokinetics in HIV Patients on Stable Antiretroviral Therapy Undergoing Analytical Treatment Interruption
Data & Insights
Has run more than one trial at 56 of 145 partner sites.
Specializations
HIV Prevention and Treatment
This investigator specializes in HIV prevention strategies and antiretroviral therapy management, with particular focus on innovative treatment approaches including long-acting injectable medications and oral drug regimens.
- Pre-exposure prophylaxis (PrEP) optimization
- Two-drug versus three-drug antiretroviral regimens
- Long-acting injectable therapeutics
The research extends to evaluating novel preventive strategies for high-risk populations.
Viral Coinfection Management
The investigator conducts research in HIV-HBV coinfection management, focusing on treatment optimization and viral control strategies.
- HIV-HBV coinfection treatment protocols
- Antiviral treatment strategies
- Long-term virological control
Work includes evaluation of treatment reduction strategies in previously controlled coinfections.
Emerging Therapeutic Approaches
Research interests include innovative immunotherapy approaches and broadly neutralizing antibodies for HIV treatment, as well as investigation of viral diseases such as mpox.
- HIV-specific antibody therapies
- Novel antiviral treatments
- Viral remission strategies
The focus includes evaluation of breakthrough therapeutic modalities for viral infections.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.